Bright Minds biosciences receives non-compliance notice from Nasdaq

• Bright Minds Biosciences (NASDAQ:DRUG) said it had received a letter from the Nasdaq stating that following the resignation of Williamson from the company’s board of directors and audit committee, the Company no longer complies with its independent director and audit committee requirements.
• The Company has until July 10 to regain compliance.
• The Company is currently in advanced discussions with a potential new director and anticipates regaining compliance within the Cure Period.